Literature DB >> 6325975

Effects of amphipathic drugs on L'[3H]glutamate binding to synaptic membranes and the purified binding protein.

E K Michaelis, C D Magruder, R A Lampe, N Galton, H H Chang, M L Michaelis.   

Abstract

Four amphipathic molecules with known local anesthetic activity, dibucaine, tetracaine, chlorpomazine, and quinacrine, inhibited the binding of L-[3H]glutamic acid to rat brain synaptic plasma membranes and to the purified glutamate binding protein. Neither haloperidol nor diphenylhydantoin had significant inhibitory effects on the glutamate binding activity of the membranes or of the purified protein. The amphipathic drugs apparently inhibited L-[3H]glutamate binding to synaptic membranes by a mixed type of inhibition. The inhibitory activity of quinacrine on glutamate binding to the synaptic membranes was greater in a low ionic strength, Ca2+-free buffer medium, than in a physiologic medium (Krebs-Henseleit buffer). Removal of Ca2+ from the Krebs solution enhanced quinacrine's inhibition of glutamate binding. Quinacrine up to 1 mM concentration did not inhibit the high affinity Na+-dependent L-glutamate transport in these membrane preparations. The importance of Ca2+ in the expression of quinacrine's effects on the glutamate binding activity of synaptic membranes and the observed tetracaine and chlorpromazine-induced increases in the transition temperature for the glutamate binding process of these membranes, were indicative of an interaction of the local anesthetics with the lipid environment of the glutamate binding sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325975     DOI: 10.1007/bf00967657

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  45 in total

1.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

2.  Calcium-induced phase separations in phosphatidylserine--phosphatidylcholine membranes.

Authors:  S Onishi; T Ito
Journal:  Biochemistry       Date:  1974-02-26       Impact factor: 3.162

3.  Comparative study of the action of phenothiazine and para-fluorobutyrophenone derivatives on rat brain membranes using the spin label technique.

Authors:  F Leterrier; F Rieger; J F Mariaud
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

4.  Comparison of tertiary and quaternary amine local anesthetics in their ability to depress membrane ionic conductances.

Authors:  T Narahashi; D T Frazier; J W Moore
Journal:  J Neurobiol       Date:  1972

5.  The effects of ethanol and chlorpromazine on the passive membrane permeability to Na + .

Authors:  P Seeman; W O Kwant; M Goldberg; M Chau-Wong
Journal:  Biochim Biophys Acta       Date:  1971-08-13

6.  The site of action and active form of local anesthetics. I. Theory and pH experiments with tertiary compounds.

Authors:  T Narahashi; T Frazier; M Yamada
Journal:  J Pharmacol Exp Ther       Date:  1970-01       Impact factor: 4.030

7.  Phospholipid model membranes. 3. Antagonistic effects of Ca2+ and local anesthetics on the permeability of phosphatidylserine vesicles.

Authors:  D Papahadjopoulos
Journal:  Biochim Biophys Acta       Date:  1970-09-15

8.  The influence of microelectrophoretically applied biogenic amines, cholinomimetics and procaine on synaptic excitation in the corpus striatum.

Authors:  A Herz; W Zieglgänsberger
Journal:  Int J Neuropharmacol       Date:  1968-05

9.  Distinguishing characteristics between glutamate and kainic acid binding sites in brain synaptic membranes.

Authors:  E K Michaelis; M L Michaelis; R D Grubbs
Journal:  FEBS Lett       Date:  1980-08-25       Impact factor: 4.124

10.  Glutamate and aspartate binding sites are enriched in synaptic junctions isolated from rat brain.

Authors:  A C Foster; E E Mena; G E Fagg; C W Cotman
Journal:  J Neurosci       Date:  1981-06       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.